Eli Lilly and Novo Nordisk dominate the billion-dollar weight loss drug market. Lilly has announced positive trial results ...

Lilly trumpeted positive topline results from ACHIEVE-1 (NCT05971940) showing orforglipron to have met the trial’s primary ...

Eli Lilly gains ground with Orforglipron’s success, showing growth potential and risks from momentum and tariffs. Read why ...

Let's look at why this news could be a game-changer for Eli Lilly and its stock.

Made in the USA, a new daily oral weight-loss pill from Eli Lilly won't require cold storage and is expected to hit markets ...

Shares of Eli Lilly soared Thursday morning after the pharmaceutical giant announced a clinical trial of its once-daily ...

The results Lilly is reporting for its oral pill come as another big drug company, Pfizer, has decided to discontinue its ...

Eli Lilly said in February that it will invest at least $27 billion to build four new manufacturing sites in the U.S. as ...

Eli Lilly completed a phase 3 trial for its weight loss drug, orforglipron, which showed promising results in evaluating its safety and efficacy for adults with Type 2 diabetes and inadequate glycemic ...

The results bring Eli Lilly's pill orforglipron one step closer to becoming a new, needle-free alternative in the booming ...

U.S. Trade Representative Jamieson Greer said the Trump Administration excluded pharmaceuticals and semiconductors from reciprocal tariffs ...